๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for B-cell Lymphoma Refractory

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites๐Ÿ“ Gilbert๐Ÿ“ Scottsdale๐Ÿ“ Scottsdale Lyell Immunopharma, Inc. ยท Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma NCT06536049Phase 1, Phase 23 sites๐Ÿ“ Minneapolis๐Ÿ“ Columbus๐Ÿ“ Richmond Yazeed Sawalha ยท Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. NCT04915248Phase 218 sites๐Ÿ“ Ancona๐Ÿ“ Aviano๐Ÿ“ Florence Fondazione Italiana Linfomi - ETS ยท Tests: Daratumumab, Bortezomib, Dexamethasone CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189Phase 11 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19x22 CAR T Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors NCT02508038Phase 11 site๐Ÿ“ Madison University of Wisconsin, Madison ยท Tests: TCRฮฑฮฒ+/CD19+ depleted Haploidentical HSCT, Zoledronate A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents NCT05334823Phase 216 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Chongqing Chongqing Precision Biotech Co., Ltd ยท Tests: pCAR-19B cells UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies NCT06743503Phase 12 sites๐Ÿ“ Nanjing๐Ÿ“ Tianjin Nanjing IASO Biotechnology Co., Ltd. ยท Tests: UB-VV400, Rapamycin Clinical Study of U01๏ผˆssCART-19๏ผ‰ in Patients With B-Cell Lymphoma NCT07093073Phase 11 site๐Ÿ“ Shanghai Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd ยท Tests: ssCART-19 Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) NCT06299553n/a1 site๐Ÿ“ Milan Incyte Biosciences Italy S.r.l A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) NCT07570173Phase 2, Phase 328 sites๐Ÿ“ Toronto๐Ÿ“ Copenhagen๐Ÿ“ Aarhus Nord Merck Sharp & Dohme LLC ยท Tests: MK-1045, Blinatumomab, Acetaminophen, Diphenhydramine, Dexamethasone Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726Phase 21 site๐Ÿ“ Seattle University of Washington ยท Tests: Odronextamab, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therโ€ฆ Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL NCT06806033Phase 253 sites๐Ÿ“ Anchorage๐Ÿ“ Clovis๐Ÿ“ Fullerton Hoffmann-La Roche ยท Tests: Obinutuzumab, Glofitamab, Gemcitabine, Oxaliplatin A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) NCT06742996Phase 3145 sites๐Ÿ“ Birmingham๐Ÿ“ Tucson๐Ÿ“ Fresno BeOne Medicines ยท Tests: Sonrotoclax, Zanubrutinib, Placebo Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Non-Hodgkin Lymphoma NCT05312801Phase 12 sites๐Ÿ“ Cleveland๐Ÿ“ Cleveland Luminary Therapeutics ยท Tests: BAFF CAR-T Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab NCT06287229Phase 1, Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD, Mini-hyper-CVD Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma NCT07126236Phase 219 sites๐Ÿ“ Seville๐Ÿ“ Zaragoza๐Ÿ“ Palma de Mallorca Grupo Espaรฑol de Linfomas y Transplante Autรณlogo de Mรฉdula โ€ฆ ยท Tests: Epcoritamab, Epcoritamab, tafasitamab and lenalidomide A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma NCT05533775Phase 1, Phase 230 sites๐Ÿ“ Birmingham๐Ÿ“ Oakland๐Ÿ“ Oakland Hoffmann-La Roche ยท Tests: Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin Epco, Zanu, Ritux for R/R FL or MZL NCT06563596Phase 23 sites๐Ÿ“ Boston๐Ÿ“ New York๐Ÿ“ Columbus Reid Merryman, MD ยท Tests: Zanubrutinib, Rituximab, Epcoritamab NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma NCT07052305Phase 11 site๐Ÿ“ St Louis Washington University School of Medicine ยท Tests: NT-I7, CAR T-cell therapy Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia NCT06581081NA1 site๐Ÿ“ Beijing Peking University People's Hospital ยท Tests: Senl_B19 autologous CAR-T (S1904) treatment Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma NCT06649812Phase 2114 sites๐Ÿ“ Tucson๐Ÿ“ Tucson๐Ÿ“ Los Angeles National Cancer Institute (NCI) ยท Tests: Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL NCT05370430Phase 16 sites๐Ÿ“ Duarte๐Ÿ“ Stanford๐Ÿ“ Kansas City PeproMene Bio, Inc. ยท Tests: BAFFR-CAR T cells A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma NCT07439653Phase 1, Phase 29 sites๐Ÿ“ Fullerton๐Ÿ“ Los Alamitos๐Ÿ“ Santa Monica TORL Biotherapeutics, LLC ยท Tests: TORL-5-700, TORL-5-700 at MTD/RP2D, TORL-5-700 at MTD/RP2D in combination with another agent Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients NCT04844866Phase 251 sites๐Ÿ“ Graz๐Ÿ“ Innsbruck๐Ÿ“ Linz Miltenyi Biomedicine GmbH ยท Tests: MB-CART2019.1, Standard of Care Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL NCT06707259Phase 11 site๐Ÿ“ Hangzhou Second Affiliated Hospital, Zhejiang University, School of โ€ฆ ยท Tests: anti-CD19 IL10/IL15 CAR-NK A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas NCT05685173Phase 120 sites๐Ÿ“ Duarte๐Ÿ“ Santa Monica๐Ÿ“ Louisville Regeneron Pharmaceuticals ยท Tests: Odronextamab, REGN5837 A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) NCT05667506Phase 1, Phase 29 sites๐Ÿ“ Hefei๐Ÿ“ Chongqing๐Ÿ“ Guangzhou Juventas Cell Therapy Ltd. ยท Tests: single dose of CNCT19 CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma NCT06209619Phase 11 site๐Ÿ“ Columbus Nathan Denlinger ยท Tests: Biopsy, Biospecimen Collection, Computed Tomography, Golcadomide, Positron Emission Tomography A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto๐Ÿ“ Aurora Autolus Limited ยท Tests: AUTO1 A Phase I Dose Finding Study of MB-CART2219.1 NCT07108868Phase 12 sites๐Ÿ“ Tรผbingen๐Ÿ“ Tรผbingen University Hospital Tuebingen ยท Tests: CAR-T cells targeting CD19 and CD22
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy